Hengqin fund registered, to focus on biomedicine investments

Zhuhai Hengqin Walvax, a private equity (PE) fund has officially registered at Asset Management Association of China (AMAC). This is the third private equity asset allocation funds of Jinsheng Capital and the sixth in China. Jinsheng became one of the first three and the only five private equity allocation fund managers in the country.

Zhuhai Hengqin Walvax, a private equity (PE) fund has officially registered at Asset Management Association of China (AMAC). This is the third private equity asset allocation funds of Jinsheng Capital and the sixth in China. Jinsheng became one of the first three and the only five private equity allocation fund managers in the country.

As of now, a total of five managers across the country have obtained private equity allocation fund manager licenses, and a total of 6 funds have been issued. Jinsheng has issued 3 PE funds with a total scale of 758 million yuan, making it the largest manager of PE funds.

Chinese financial management firm Jinsheng Capital has partnered with Shenzhen-listed biopharma enterprise Walvax Biotechnology to set up Zhuhai Hengqin Walvax, a private equity (PE) fund with a focus on biomedicine investments, according to a company statement.

Zhuhai Hengqin Walvax is a cross-asset allocation fund with a focus on biomedicine investments. It will work closely with leading companies in the biopharmaceutical industry. Leveraging the unique advantages of PE funds, it focuses on investing in high-quality upstream and downstream assets in biomedicine.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/06/hengqin-fund-registered-to-focus-on-biomedicine-investments/.

Leave a Reply

Please Login to Comment